We provide high throughput, targeted and whole genome sequencing in a CAP and DAP certified laboratory. Our combination of scientific, technical, informatic and clinical expertise means  you can be confident that our data and diagnostics are of the highest quality.

Learn More:

The GSC is CAP and DAP certified to provide whole genome sequencing up to the production of BAM files.

Our Oncopanel detects mutations with known occurrence in the development of solid tumours within the following 48 genes:

AKT1, ALK, APC, ATM, BMPR1A, BRAF, BRCA1, BRCA2, CDH1, CDK4, CDKN2A, CHEK2, CIC, EGFR, ERBB2 (HER2), ERBB3 (HER3), FUBP1, GNAQ, GNA11, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1 (MEK1), MET (HGFR), MLH1, MSH2, MSH6, MUTYH, NF1, NRAS, PALB2, PDGFRA, PIK3CA, PMS2, POLD1, POLE, PTEN, RET, ROS1, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53.

The current turnaround time is 12-17 days from receipt of the sample to mailing of the report.

If ordering within British Columbia, please refer to the Cancer Genetics Lab website.

If ordering from outside of British Columbia, please contact us for details and requisition forms.

The development of our next-generation sequencing assay is described in Bosdet et al. 2013.

Our Myeloid Panel detects mutations associated with acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndromes, in the following 52 genes:

ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DKC1, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KDM6A, KIT, KMT2A(MLL), KRAS, MPL, NF1, NPM1, NRAS, PHF6, PIGA, PRPF40B, PTEN, PTPN11, RAD21, RTEL1, RUNX1, SETD2, SF1, SF3A1, SF3B1, SH2B3, SMC1A, SMC3, SOCS3, SRSF2, STAG2, TERC, TERT, TET2, TP53, U2AF1, U2AF2, WT1, ZRSR2.

The current turnaround time is 12-17 days from receipt of the sample to mailing of the report.

If ordering within British Columbia, please refer to the Cancer Genetics Lab website.

If ordering from outside of British Columbia, please contact us for details and requisition forms.

The development of our next-generation sequencing assay is described in Bosdet et al. 2013.

Our Hereditary Cancer Panel is available to people across Canada and includes testing for mutations in the following 19 genes:

APC, ATM, BMPR1A, BRCA1, BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53

This panel replaced BRCA1/2 testing in British Columbia in October 2014.

Current turnaround time is 8 weeks.

A list of ACMG 1, 2 and 3 variants with clinical interpretation will be reported.

Variants in exons 12 and 15 of PMS2 are not reported.

MLPA for copy number changes is offered for BRCA1, BRCA2, MLH1 and MSH2 upon request.

Referrals for this assay must be requested through BC Cancer's Hereditary Cancer Program.

If ordering from outside of British Columbia, please contact us for details and requisition forms.

Questions?

Didn't find what you're looking for?
Please feel free to contact one of our Platform Leaders directly.

Or tell us about your project and how we can help:

Indicates required field
Thank you for your interest in our Collaborative Services. For us to provide you with information most suitable for your work, please fill out the form below with your contact details, a brief description of your project and which of the services you are interested in.
Are you affiliated with BC Cancer?
Which products are you interested in:
Sequencing
Bioinformatics
Proteomics
Canada’s Michael Smith Genome Sciences Centre at BC Cancer is committed to protecting and respecting your privacy. We only use your personal information to provide the services you request from us. From time to time, we would like to contact you about our research and services, as well as other related content that may be of interest to you. We do not share your contact information with any third parties, and you may unsubscribe from our communications at any time. We comply with the Provincial Health Services Authority’s (PHSA) Privacy Policy. By clicking submit below, you consent to allow Canada’s Michael Smith Genome Sciences Centre to store and process the personal information submitted above to provide you the content requested.
Back to top